InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Explore the detailed record of transactions filed by CHURCH KEVIN, Vice-Président de la Découverte. Officer active across 1 company, notably Athira Pharma, Inc.. Aggregated, 17 reports have been recorded. Activity tracked since 8 June 2021. The latest transaction was filed on 18 November 2024 (Attribution). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations17 total
9,920 shares@ US$0.5510.4% of flowCommon StockSEC:0001415889-25-000534:0
4,953 shares@ US$1.3412.3% of flowCommon StockSEC:0001415889-24-022985:0
809 shares@ US$2.413.6% of flowCommon StockSEC:0001415889-24-004146:0
809 shares@ US$2.413.6% of flowCommon StockSEC:0001209191-24-001142:0
6,410 shares@ US$1.3516.0% of flowCommon StockSEC:0001209191-23-021248:0
657 shares@ US$2.743.5% of flowCommon StockSEC:0001209191-23-004468:0
3,700 shares@ US$1.3510.1% of flowCommon StockSEC:0001209191-22-054950:0
10,000 shares0Common StockSEC:0001209191-22-039336:0
243 shares@ US$7.068.1% of flowCommon StockSEC:0001209191-22-036067:0
3,152 shares@ US$1.1935.7% of flowCommon StockSEC:0001209191-22-011485
3,152 shares@ US$1.1916.4% of flowCommon StockSEC:0001209191-22-011485:0
96 shares@ US$12.515.3% of flowCommon StockSEC:0001209191-22-004118:0
96 shares@ US$12.512.1% of flowCommon StockSEC:0001209191-22-004118
185 shares@ US$14.454.4% of flowCommon StockSEC:0001209191-21-039625
185 shares@ US$14.4510.9% of flowCommon StockSEC:0001209191-21-039625:0
3,152 shares@ US$1.0413.4% of flowCommon StockSEC:0001209191-21-039242:0
3,152 shares@ US$1.045.4% of flowCommon StockSEC:0001209191-21-039242
17 of 17 declarations
About CHURCH KEVIN
Kevin Church is the Vice President of Discovery and Executive VP, Research at Athira Pharma, Inc. In this role, he is responsible for leading research efforts to discover new therapies. His extensive experience in pharmaceutical research enables him to guide teams in developing innovative solutions for neurological diseases. His leadership is crucial in advancing research projects and achieving the company's objectives.
